View ValuationOctopus Biosafety 将来の成長Future 基準チェック /06現在、 Octopus Biosafetyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長24.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (172% average daily change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.56m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).New Risk • Jun 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 170% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (170% average daily change). Revenue is less than US$1m (€656k revenue, or US$746k). Market cap is less than US$10m (€1.66m market cap, or US$1.88m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray Franceお知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence FranceNew Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jun 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$577k). Market cap is less than US$10m (€1.34m market cap, or US$1.44m).お知らせ • Nov 25Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS.Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS on November 24, 2022.Octopus Biosafety SA (ENXTPA:MLOCT) completed the acquisition of TIBOT Technologies SAS on November 24, 2022.Is New 90 Day High Low • Dec 01New 90-day low: €1.50The company is down 50% from its price of €3.00 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Octopus Biosafety は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BST:OCR - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20240-1N/AN/AN/A12/31/20231-2N/AN/AN/A12/31/20220-1N/AN/AN/A12/31/20211-1N/AN/AN/A12/31/20201-1N/AN/AN/A12/31/20190-1N/AN/AN/A7/31/201710N/AN/AN/A6/30/201600N/AN/AN/A6/30/201500N/AN/AN/Aアナリストによる今後の成長予測収入対貯蓄率: OCRの予測収益成長が 貯蓄率 ( 1.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OCRの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OCRの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OCRの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OCRの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OCRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/09/23 18:57終値2025/06/26 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Octopus Biosafety SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (172% average daily change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.56m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).
New Risk • Jun 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 170% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (170% average daily change). Revenue is less than US$1m (€656k revenue, or US$746k). Market cap is less than US$10m (€1.66m market cap, or US$1.88m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).
お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France
お知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence France
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jun 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$577k). Market cap is less than US$10m (€1.34m market cap, or US$1.44m).
お知らせ • Nov 25Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS.Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS on November 24, 2022.Octopus Biosafety SA (ENXTPA:MLOCT) completed the acquisition of TIBOT Technologies SAS on November 24, 2022.
Is New 90 Day High Low • Dec 01New 90-day low: €1.50The company is down 50% from its price of €3.00 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 6.0% over the same period.